首页> 外文期刊>Reviews on recent clinical trials >ACE inhibitors for the treatment of hypertension drug selection by means of the SOJA method.
【24h】

ACE inhibitors for the treatment of hypertension drug selection by means of the SOJA method.

机译:ACE抑制剂可通过SOJA方法治疗高血压药物。

获取原文
获取原文并翻译 | 示例
           

摘要

ACE inhibitors have proven to be effective blood pressure lowering agents with an excellent tolerability profile. The family of these drugs is still expanding, necessitating the definition of selection criteria in order to choose the "right drug". In this article the ACE inhibitors available in the United Kingdom (UK) are scored by means of the SOJA method. The System of Objectified Judgement Analysis (SOJA) method is a model for rational drug selection. The relevant selection criteria for a certain group of drugs are defined and judged by a panel of experts and each selection criterion is given a relative weight. The more important that a selection criterion is considered, the higher the relative weight that is given to that criterion. The ideal properties for each selection criterion are determined and each drug is scored as a percentage of the score of the ideal drug for all selection criteria. The following selection criteria were used (relative weight): number of formulations (20), number of indications (20), variation in bioavailability (40), interactions (40), trough/peak ratio diastolic blood pressure lowering effect (20), efficacy (250), side-effects (150), dosage frequency (100), documentation (100) and effect on clinical endpoints (260). Ramipril showed the highest score, followed by perindopril, lisinopril and enalapril. The well documented effects on clinically relevant end points, such as cardiovascular morbidity and mortality contributed to the high score for ramipril.
机译:ACE抑制剂已被证明是有效的降血压药,具有出色的耐受性。这些药物的家庭仍在扩大,因此有必要定义选择标准以选择“正确的药物”。本文通过SOJA方法对英国(UK)可获得的ACE抑制剂进行评分。客观判断分析系统(SOJA)方法是合理选择药物的模型。由一组专家定义和判断针对某类药物的相关选择标准,并为每个选择标准赋予相对权重。考虑选择标准越重要,赋予该标准的相对权重就越高。确定每种选择标准的理想特性,并对每种药物评分,作为所有选择标准的理想药物分数的百分比。使用以下选择标准(相对重量):制剂数量(20),适应症数量(20),生物利用度变化(40),相互作用(40),低谷/峰值比率舒张压降低血压(20),功效(250),副作用(150),给药频率(100),文献(100)以及对临床终点的影响(260)。雷米普利得分最高,其次是培哚普利,赖诺普利和依那普利。对临床相关终点(如心血管疾病的发病率和死亡率)的有据可查的影响使雷米普利得分高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号